GLP-1 receptor agonists yield 2.5-4x greater weight loss in non-diabetics than diabetics

While glucagon-like peptide-1 (GLP-1) receptor agonists are a cornerstone therapy for obesity management, their long-term comparative effectiveness across diabetes status, adherence, and specific agents remains unclear. Understanding these differential impacts is crucial for optimizing treatment strategies and personalizing care. This meta-analysis addresses the critical gap in characterizing medication- and phenotype-specific differences in weight loss outcomes.

This study conducted a subgroup analysis of a large-scale meta-analysis, encompassing 56,580 patients from 45 clinical trials, observational, and case-control studies published between 2010 and 2025. Researchers evaluated long-term weight outcomes for various GLP-1 agents, stratifying results by diabetes status (diabetic vs. non-diabetic) and adherence (mixed, intention-to-treat, adherent populations). Mixed-effects meta-regression was performed to identify independent predictors of weight loss, comparing agents like semaglutide and liraglutide.

GLP-1 therapy consistently induced greater weight loss than placebo across all populations studied. Non-diabetic participants achieved significantly greater reductions, losing 15.7% of baseline weight at 12 months compared to 5.1% in diabetic users within the mixed cohort. This represented a 2.5-4x greater reduction for non-diabetic individuals receiving the same agents. Intention-to-treat (ITT) results were similar but modestly attenuated, while adherent patients demonstrated the largest reductions overall. Meta-regression confirmed diabetes status as a strong independent negative predictor of weight loss (β =  -1.77, p < 0.001). Furthermore, semaglutide produced significantly greater reductions than liraglutide after adjustment (β =  +1.67, p < 0.001), and baseline BMI was inversely associated with percent weight change (β =  +0.46, p < 001).